From Pulse 2.0 · Amit Chowdhry · · 1m
Filana Therapeutics Appoints Jill Quigley to Board
Filana Therapeutics adds Jill Quigley to its board ahead of simufilam Phase 2a study in TSC-related epilepsy.
In brief
Filana Therapeutics adds Jill Quigley to its board ahead of simufilam Phase 2a study in TSC-related epilepsy. Filana Therapeutics appointed Jill M. Quigley as independent director to support its simufilam Phase 2a clinical study for TSC-related epilepsy starting in Q1 2027. Originally reported by Pulse 2.0.
Filana Appoints Jill Quigley
Filana Therapeutics appointed Jill M. Quigley as independent director with over 20 years of biotech experience.
Simufilam for TSC Epilepsy
Filana develops simufilam to treat epilepsy associated with tuberous sclerosis complex.
Tuberous Sclerosis Complex
Tuberous sclerosis complex causes noncancerous tumors in multiple organs including the brain.
Phase 2a Study Timeline
Filana expects patient screening for simufilam study to begin by first quarter of 2027.
Jill Quigley's Background
Quigley served as CEO of a preclinical biotech company since November 2026.
Board Expertise for Clinical Development
Quigley's experience helps Filana oversee clinical strategy and capital requirements for simufilam study.
The takeaway
Filana Therapeutics appointed Jill M. Quigley as independent director to support its simufilam Phase 2a clinical study for TSC-related epilepsy starting in Q1 2027.
